Cell Based Therapies for ARDS | Michael A. Matthay, MD

LOMA LINDA University in association with Breathe Southern California and Trudeau Society Present: Philip Gold, M.D.Distinguished Scholar Lecture: Virtual Online

Cell Based Therapies for ARDS

Michael Matthay, MD, Director of the Critical Care Medicine ‐ University of California San Francisco

EEDS LINK TO JOIN VIRTUALLY

About The Speaker

Michael A. Matthay, MD is a Professor of Medicine and Anesthesia at the University of California at San Francisco and a Senior Associate at the Cardiovascular Research Institute. He is Associate Director of the Critical Care Medicine Training in the Department of Medicine and Associate Director of the Intensive Care Unit. He received his AB from Harvard University and his MD from the University of Pennsylvania School of Medicine. Dr. Matthay received clinical training in Internal Medicine at the University of Colorado from and in Pulmonary and Critical Care Medicine from the University of California at San Francisco. He also received research training from the Cardiovascular Physiology Laboratory, University of Colorado and the Cardiovascular Research Institute.

Research Interests: Dr. Matthay’s basic research is focused on active ion and water transport mechanisms that account for the resolution of pulmonary edema as well as mechanisms that account for alveolar epithelial repair after acute lung injury. The studies are carried out in several in vivo and in vitro models. Dr. Matthay’s clinical research is focused on the mechanisms that account for the pathogenesis and resolution of clinical acute lung injury and pulmonary edema. His laboratory has approximately 5-6 fellows with a mixture of PhD and MD fellows with weekly research conferences that include both basic and clinical research topics. He also has directed several phase 2 and 3 clinical trials supported by the NIH including ARDS Net and the PETAL networks and been an Investigator for several trials in COVID-19 and sepsis. He has a major time commitment to training residents, fellows and junior faculty for a career in academic medicine.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

• Discuss the mechanisms by which mesenchymal stromal cells can reduce lung injury in pre‐clinical studies
• Review results of clinical trials for classical ARDS and COVID‐19 ARDS
• Consider the steps forward to find the treatment responsive sub‐groups of ARDS patients for mesenchymal cells or mesenchymal cell‐derived treatments

Accreditation Statement:

The Loma Linda University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education ﴾ACCME﴿ to provide continuing medical education for physicians.

Disclosure Statement

This program has been planned and implemented in accordance with ACCME essentials and standards. The Loma Linda University School of Medicine Office of Continuing Medical Education relies on its CME faculty to provide program content that is free of commercial bias. Therefore, in accordance with ACCME standards, any faculty and/or provider industry relationships will be disclosed and resolved.

Credit Designation:

The Loma Linda University School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EEDS LINK TO JOIN VIRTUALLY